| Kang G Chan, MD MPH | |
|
364 Shea Drive, New Milford, NJ 07646-1033 | |
| (201) 385-9767 | |
| Not Available |
| Full Name | Kang G Chan |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 364 Shea Drive, New Milford, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356549117 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 0101033445 (Virginia) | Primary |
| 2083X0100X | Preventive Medicine - Occupational Medicine | 0101033445 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kang G Chan, MD MPH 364 Shea Drive, New Milford, NJ 07646-1033 Ph: (201) 385-9767 | Kang G Chan, MD MPH 364 Shea Drive, New Milford, NJ 07646-1033 Ph: (201) 385-9767 |
News Archive
There is good news for the 76 million Americans who experience chronic pain including migraine, back pain, fibromyalgia and arthritis. A new study reveals that an online, self-paced chronic pain management program reduces the physical and psychological burdens of this debilitating condition.
Early surgery may not be the best treatment option for patients with Type V AC joint injuries, according to new research from Tripler Army Medical Center. The study, presented today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Specialty Day, showed military personnel returned to duty faster when surgery was not performed.
A new study from researchers at the Stanford University School of Medicine has identified a unique protein complex that can be used to predict whether an epidural steroid injection will help relieve pain caused by a herniated disc in the lower spine.
Cutting edge research into an experimental therapy that deploys nano-particles of gold in the fight against cancer earned an Alberta high school student, 16, top national honours today in the 2013 "Sanofi BioGENEius Challenge Canada" (SBCC).
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 8 days ago